WE CLAIM:

1. A pharmaceutical composition comprising
tirzepatide, or a pharmaceutically acceptable salt thereof;
an agent selected from the group consisting of NaCl and propylene glycol;and
dibasic sodium phosphate.
2. A pharmaceutical composition as claimed by Claim 1, wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is from about 5 to about 30 mg/mL.
3. A pharmaceutical composition as claimed by Claim 2
wherein the dibasic sodium phosphate concentration is from about 1.0 mg/mL to about 3.0 mg/mL.
4. A pharmaceutical composition as claimed by Claim 3 wherein the dibasic sodium phosphate concentration is from about 0.67 mg/mL to about 2.68 mg/mL.
5. A pharmaceutical composition as claimed by Claim 4 wherein the dibasic sodium phosphate concentration is about 1.34 mg/mL.
6. A pharmaceutical composition as claimed by Claim 1 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and
30 mg/mL.
7. A pharmaceutical composition as claimed by Claim 6 wherein the tirzepatide, or pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 10, 20, and 30 mg/mL.
8. A pharmaceutical composition as claimed by Claim 7
wherein the agent is NaCl.
9. A pharmaceutical composition as claimed by Claim 8 wherein the concentration of NaCl is from about 6.2 mg/mL to about 9.5 mg/mL.
10. A pharmaceutical composition as claimed by Claim 9
wherein the concentration of NaCl is from about 7.0 mg/mL to about 9.0 mg/mL.

11. A pharmaceutical composition as claimed by Claim 10 wherein the NaCl concentration is about 8.2 mg/mL.
12. A pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate concentration is from about 0.67 mg/mL to about 2.68 mg/mL; and NaCl concentration is from about 6.2 mg/mL to about 9.5 mg/mL.
13. A pharmaceutical composition as claimed by Claim 12 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate concentration is about 1.34 mg/mL; and NaCl concentration is about 8.2 mg/mL.
14. A pharmaceutical composition as claimed by Claim 13 wherein the composition is presented in an automatic injection apparatus.
15. A pharmaceutical composition as claimed by Claim 1 wherein the agent is propylene glycol.
16. A pharmaceutical composition as claimed by Claim 15 wherein the concentration of propylene glycol is from about 12.0 mg/mL to about 18.0 mg/mL.
17. A pharmaceutical composition as claimed by Claim 16 wherein the concentration of propylene glycol is from about 14.0 mg/mL to about 16.0 mg/mL.
18. A pharmaceutical composition as claimed by Claim 17 wherein the concentration of propylene glycol is about 15.0 mg/mL.
19. A pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate concentration is from about 0.67 mg/mL to about 2.68 mg/mL; and propylene glycol concentration is from about 14.0 mg/mL to about 16.0 mg/mL.
20. A pharmaceutical composition as claimed by Claim 19 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate concentration is about 1.34 mg/mL; and propylene glycol concentration is about 15.0 mg/mL.

21. A pharmaceutical composition as claimed by Claim 20 wherein the composition is presented in an automatic injection apparatus.

22. A pharmaceutical composition as claimed by Claim 21 wherein the pH of the composition is from about 6.5 to about 7.5.

23. A pharmaceutical composition as claimed by Claim 22 wherein the pH is from about 6.7 to about 7.3.

24. A pharmaceutical composition as claimed by Claim 23 further comprising one or more preservatives.

25. A pharmaceutical composition as claimed by Claim 24 wherein the composition further comprises a preservative selected from the group consisting of metacresol and phenol.

26. A pharmaceutical composition as claimed by Claim 25 wherein the preservative is metacresol.

27. A pharmaceutical composition as claimed by Claim 26 wherein the metacresol concentration is from about 2.0 mg/mL to about 4.0 mg/mL.

28. A pharmaceutical composition as claimed by Claim 27 wherein the metacresol concentration is about 3.15 mg/mL.

29. A pharmaceutical composition as claimed by Claim 25 wherein the preservative is phenol.

30. A pharmaceutical composition as claimed by Claim 29 wherein the phenol concentration is from about 3.0 mg/mL to about 7.0 mg/mL.

31. A pharmaceutical composition as claimed by Claim 30 wherein the phenol concentration is about 5.0 mg/mL.

32. A pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; propylene glycol is from about 12.0 mg/mL to about 15.0 mg/mL; and further comprising from about 2.0 mg/mL to about 4.0 mg/mL metacresol.

33. A pharmaceutical composition as claimed by Claim 1 wherein tirzepatide, or pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate is from about 0.67 to

about 2.68 mg/mL; propylene glycol is from about 12.0 mg/mL to about 18.0 mg/mL; and further comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol.

34. A pharmaceutical composition as claimed by Claim 33 wherein the volume of the composition dose is about 0.5 mL.

35. A pharmaceutical composition as claimed by Claim 34 wherein the composition is administered using an automatic injection apparatus.

36. A method of treating diabetes comprising administering to a human in need thereof an effective dose of the pharmaceutical composition as claimed by Claim 33.

37. A method of treating diabetes as claimed by Claim 36 wherein the dose is administered using an automatic injection apparatus.

38. A method of treating diabetes as claimed by Claim 37 wherein the dose is administered once weekly.

39. A method of treating obesity comprising administering to a human in need thereof an effective dose of the pharmaceutical composition as claimed by Claim 33.

40. A method of treating obesity as claimed by Claim 39 wherein the dose is administered using an automatic injection apparatus.

41. A method of treating obesity as claimed by Claim 40 wherein the dose is administered once weekly.

42. A pharmaceutical composition as claimed by Claim 33 for use in the treatment of diabetes.

43. A pharmaceutical composition as claimed by Claim 33 for use in the treatment of obesity.